BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1044 related articles for article (PubMed ID: 28985567)

  • 1. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
    Reddy A; Zhang J; Davis NS; Moffitt AB; Love CL; Waldrop A; Leppa S; Pasanen A; Meriranta L; Karjalainen-Lindsberg ML; Nørgaard P; Pedersen M; Gang AO; Høgdall E; Heavican TB; Lone W; Iqbal J; Qin Q; Li G; Kim SY; Healy J; Richards KL; Fedoriw Y; Bernal-Mizrachi L; Koff JL; Staton AD; Flowers CR; Paltiel O; Goldschmidt N; Calaminici M; Clear A; Gribben J; Nguyen E; Czader MB; Ondrejka SL; Collie A; Hsi ED; Tse E; Au-Yeung RKH; Kwong YL; Srivastava G; Choi WWL; Evens AM; Pilichowska M; Sengar M; Reddy N; Li S; Chadburn A; Gordon LI; Jaffe ES; Levy S; Rempel R; Tzeng T; Happ LE; Dave T; Rajagopalan D; Datta J; Dunson DB; Dave SS
    Cell; 2017 Oct; 171(2):481-494.e15. PubMed ID: 28985567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.
    Giannuzzi D; Marconato L; Fanelli A; Licenziato L; De Maria R; Rinaldi A; Rotta L; Rouquet N; Birolo G; Fariselli P; Mensah AA; Bertoni F; Aresu L
    Lab Anim (NY); 2022 Jul; 51(7):191-202. PubMed ID: 35726023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
    Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
    Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
    Lohr JG; Stojanov P; Lawrence MS; Auclair D; Chapuy B; Sougnez C; Cruz-Gordillo P; Knoechel B; Asmann YW; Slager SL; Novak AJ; Dogan A; Ansell SM; Link BK; Zou L; Gould J; Saksena G; Stransky N; Rangel-Escareño C; Fernandez-Lopez JC; Hidalgo-Miranda A; Melendez-Zajgla J; Hernández-Lemus E; Schwarz-Cruz y Celis A; Imaz-Rosshandler I; Ojesina AI; Jung J; Pedamallu CS; Lander ES; Habermann TM; Cerhan JR; Shipp MA; Getz G; Golub TR
    Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3879-84. PubMed ID: 22343534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity of diffuse large B-cell lymphoma.
    Zhang J; Grubor V; Love CL; Banerjee A; Richards KL; Mieczkowski PA; Dunphy C; Choi W; Au WY; Srivastava G; Lugar PL; Rizzieri DA; Lagoo AS; Bernal-Mizrachi L; Mann KP; Flowers C; Naresh K; Evens A; Gordon LI; Czader M; Gill JI; Hsi ED; Liu Q; Fan A; Walsh K; Jima D; Smith LL; Johnson AJ; Byrd JC; Luftig MA; Ni T; Zhu J; Chadburn A; Levy S; Dunson D; Dave SS
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1398-403. PubMed ID: 23292937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
    Miyazaki K
    Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.
    Jardin F
    Discov Med; 2014; 18(97):51-65. PubMed ID: 25091488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
    Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
    Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
    Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
    EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.